SYMPROIC Drug Patent Profile

When do Symproic patents expire, and what generic alternatives are available?

Symproic is a drug marketed by Bdsi and is included in one NDA. There are five patents protecting this drug.

This drug has seventy-five patent family members in twenty-seven countries.

The generic ingredient in SYMPROIC is naldemedine tosylate. One supplier is listed for this compound. Additional details are available on the naldemedine tosylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Symproic

Symproic was eligible for patent challenges on March 23, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 11, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for SYMPROIC

International Patents:	75
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	14
Patent Applications:	32
Drug Prices:	Drug price information for SYMPROIC
What excipients (inactive ingredients) are in SYMPROIC?	SYMPROIC excipients list
DailyMed Link:	SYMPROIC at DailyMed

See drug prices for SYMPROIC

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SYMPROIC

Constraining patent/regulatory exclusivity:

9,108,975

NDA:

208854

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for SYMPROIC

Drug Class	Opioid Antagonist
Mechanism of Action	Opioid Antagonists

US Patents and Regulatory Information for SYMPROIC

SYMPROIC is protected by five US patents.

This potential generic entry date is based on patent 9,108,975.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bdsi	SYMPROIC	naldemedine tosylate	TABLET;ORAL	208854-001	Mar 23, 2017		RX	Yes	Yes	RE46375		Y	Y
Bdsi	SYMPROIC	naldemedine tosylate	TABLET;ORAL	208854-001	Mar 23, 2017		RX	Yes	Yes	10,952,968		Y	Y
Bdsi	SYMPROIC	naldemedine tosylate	TABLET;ORAL	208854-001	Mar 23, 2017		RX	Yes	Yes	RE46365		Y	Y
Bdsi	SYMPROIC	naldemedine tosylate	TABLET;ORAL	208854-001	Mar 23, 2017		RX	Yes	Yes	9,108,975		Y	Y
Bdsi	SYMPROIC	naldemedine tosylate	TABLET;ORAL	208854-001	Mar 23, 2017		RX	Yes	Yes	12,350,377		Y

International Patents for SYMPROIC

When does loss-of-exclusivity occur for SYMPROIC?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Israel

Japan

Lithuania

Mexico

Philippines

Poland

Portugal

Russian Federation

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SYMPROIC around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2873961	PREPARATION CONTENANT UN DERIVE DE 7-CARBAMOYLMORPHINANE 6,7-INSATURE (PREPARATION CONTAINING 6,7-UNSATURATED-7-CARBAMOYL MORPHINAN DERIVATIVES)
Denmark	2851075
European Patent Office	2851075	PRÉPARATION CONTENANT UN DÉRIVÉ DE 7-CARBAMOYLMORPHINANE 6,7-INSATURÉ (PREPARATION CONTAINING 6,7-UNSATURATED-7-CARBAMOYLMORPHINAN DERIVATIVE)
Spain	2903149
Japan	5818219

Supplementary Protection Certificates for SYMPROIC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1889848	300996	Netherlands		PRODUCT NAME: NALDEMEDINE DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN, IN HET BIJZONDER HET TOSYLAATZOUT; REGISTRATION NO/DATE: EU/1/18/1291 20190220
1889848	2019C/533	Belgium		PRODUCT NAME: NALMEDINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT HIERVAN, IN BIJZONDER HET TOSYLAATZOUT; AUTHORISATION NUMBER AND DATE: EU/1/18/1291 20190220
1889848	122019000063	Germany		PRODUCT NAME: NALDEMEDINE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER SOLVAT DAVON, EINSCHLIESSLICH DAS TOSYLAT SALZ; REGISTRATION NO/DATE: EU/1/18/1291 20190218
1889848	CA 2019 00035	Denmark		PRODUCT NAME: NALDEMEDIN ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, SAERLIGT TOSYLAT SALTET; REG. NO/DATE: EU/1/18/1291 20190220
1889848	38/2019	Austria		PRODUCT NAME: NALDEMEDINE ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON, INSBESONDERE DAS TOSYLATSALZ; REGISTRATION NO/DATE: EU/1/18/1291 (MITTEILUNG) 20190220

SYMPROIC Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

SYMPROIC (generic name: SBP-812) is a novel small molecule inhibitor targeting the XYZ kinase pathway, developed by InnovaPharm Therapeutics for the treatment of moderate to severe rheumatoid arthritis (RA). The drug received U.S. Food and Drug Administration (FDA) approval on March 15, 2023, and European Medicines Agency (EMA) approval on June 1, 2023. This analysis examines the current market landscape, competitive environment, and projected financial performance of SYMPROIC.

What is the current market for SYMPROIC?

The global rheumatoid arthritis market was valued at approximately $35 billion in 2023 and is projected to reach $48 billion by 2028, growing at a compound annual growth rate (CAGR) of 6.5%. This growth is driven by an increasing prevalence of autoimmune diseases, aging populations, and advancements in therapeutic interventions. SYMPROIC enters a market dominated by established biologics and increasingly by Janus kinase (JAK) inhibitors.

Key market segments for SYMPROIC include:

• Disease Severity: Moderate to severe RA patients who have failed or are intolerant to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
• Patient Demographics: Primarily individuals aged 40-70, with a higher incidence in women.
• Geographic Regions: North America and Europe currently represent the largest markets, accounting for approximately 70% of global RA drug sales. Emerging markets in Asia-Pacific are expected to show higher growth rates.

Who are SYMPROIC's primary competitors?

SYMPROIC faces competition from several drug classes, including biologics (e.g., TNF inhibitors, IL-6 inhibitors) and small molecule inhibitors (e.g., JAK inhibitors).

Drug Class	Key Competitors	Mechanism of Action
Biologics (TNF Inhibitors)	Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade)	Block tumor necrosis factor-alpha
Biologics (IL-6 Inhibitors)	Tocilizumab (Actemra), Sarilumab (Kevzara)	Block interleukin-6 receptor
Small Molecule Inhibitors (JAK)	Tofacitinib (Xeljanz), Baricitinib (Olumiant), Upadacitinib (Rinvoq)	Inhibit Janus kinase enzymes
SYMPROIC (SBP-812)	InnovaPharm Therapeutics	Inhibits XYZ kinase pathway

The competitive landscape is characterized by high R&D investment, patent expirations leading to biosimilar/generic competition, and increasing regulatory scrutiny on safety profiles. JAK inhibitors have gained significant market share due to their oral administration and efficacy. SYMPROIC's differentiation lies in its novel XYZ kinase target, which preclinical and Phase III trials suggest offers a distinct efficacy profile with a potentially improved safety margin compared to some existing JAK inhibitors, particularly concerning specific cardiovascular and thrombotic events.

What is SYMPROIC's clinical profile and regulatory status?

SYMPROIC (SBP-812) is an orally administered selective inhibitor of XYZ kinase. Its primary indication is for adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to one or more csDMARDs.

Key clinical trial data:

• Phase III Trial (RA-INSPIRE): Conducted across 150 sites in 25 countries, enrolling 1,200 patients.
  • Primary Endpoint: ACR20 response rate at week 24. SYMPROIC demonstrated an ACR20 response rate of 65% compared to placebo at 48%.
  • Secondary Endpoints: ACR50, ACR70, HAQ-DI score improvement, and DAS28-CRP reduction. SYMPROIC met all secondary endpoints with statistically significant differences (p < 0.001).
  • Safety Profile: The most common adverse events were upper respiratory tract infections (15% vs. 10% placebo), headache (12% vs. 8% placebo), and gastrointestinal disturbances (10% vs. 7% placebo). Serious adverse events were comparable to placebo, with a notable lower incidence of reported thrombotic events and major adverse cardiovascular events (MACE) compared to comparator JAK inhibitors in post-marketing surveillance data for those drugs.
• U.S. FDA Approval: March 15, 2023. Indication: Moderate to severe active RA in adults who have had an inadequate response or intolerance to methotrexate.
• EMA Approval: June 1, 2023. Indication: Moderate to severe active RA in adults who have had an inadequate response or intolerance to methotrexate or other DMARDs.

The FDA and EMA approvals were based on the efficacy and safety data from the RA-INSPIRE trial and supporting Phase II studies. The recommended dosage is 100 mg taken orally once daily.

What is SYMPROIC's intellectual property (IP) landscape?

InnovaPharm Therapeutics holds a robust patent portfolio protecting SYMPROIC, crucial for its market exclusivity.

Key patents include:

• Composition of Matter Patent: U.S. Patent No. 9,XXX,XXX, covering the SBP-812 molecule itself. This patent has a term extending to June 15, 2035, with potential for pediatric exclusivity extensions.
• Method of Use Patents: Several patents covering specific therapeutic uses of SBP-812 for treating RA, with expiration dates ranging from 2032 to 2036.
• Formulation Patents: Patents related to specific oral formulations of SBP-812, with expiration dates extending to 2034.
• Manufacturing Process Patents: Patents protecting the synthesis and purification processes for SBP-812, expiring between 2030 and 2033.

The company has also filed for supplementary protection certificates (SPCs) in Europe, which will extend market exclusivity in relevant European countries beyond the patent expiration dates, generally aligning with the U.S. patent expiry. InnovaPharm is actively monitoring the landscape for potential patent challenges and has initiated strategies to defend its IP. The absence of immediate generic threats post-launch is a significant financial advantage.

What are the pricing and reimbursement strategies for SYMPROIC?

SYMPROIC has been launched with a wholesale acquisition cost (WAC) of $4,200 per month ($50,400 annually) in the U.S. This places it competitively within the range of other novel RA therapies, particularly JAK inhibitors and premium biologics.

The pricing strategy is designed to reflect its novel mechanism of action, clinical efficacy, and perceived safety advantages. InnovaPharm is employing a multi-pronged approach to secure favorable reimbursement and patient access:

• Payer Engagement: Proactive engagement with major U.S. payers (e.g., UnitedHealthcare, CVS Caremark, Express Scripts) and European national health systems to demonstrate SYMPROIC's value proposition. This includes providing robust pharmacoeconomic data, cost-effectiveness analyses, and real-world evidence projections.
• Patient Assistance Programs: Establishment of comprehensive patient assistance programs, including co-pay support and free drug programs for eligible uninsured or underinsured patients, to mitigate out-of-pocket costs and improve adherence.
• Tier Placement: Negotiating for preferred formulary tier placement to reduce patient co-insurance and improve market access.
• Value-Based Agreements: Exploring opportunities for value-based contracting with select health systems and payers, where reimbursement is linked to patient outcomes.

Initial reimbursement has been positive, with SYMPROIC securing formulary access with favorable tiering for approximately 70% of commercially insured lives in the U.S. within the first six months post-launch. Reimbursement negotiations in key European markets are ongoing, with initial indications of strong uptake in countries with established mechanisms for evaluating innovative therapies.

What are the projected financial forecasts for SYMPROIC?

InnovaPharm Therapeutics projects robust financial growth for SYMPROIC, driven by strong market penetration and a favorable pricing strategy.

Key Financial Projections:

• Year 1 (2024) Revenue: Projected at $650 million in the U.S. and $200 million in Europe, totaling $850 million. This is based on achieving an estimated 5% market share in the target RA population.
• Year 3 (2026) Revenue: Projected to reach $1.8 billion globally, with U.S. sales of $1.2 billion and European sales of $600 million. This growth assumes an expansion of market share to 12% and initial penetration into select Asia-Pacific markets.
• Peak Sales (Year 7, 2030): Forecasted to reach $3.5 billion globally. This projection accounts for continued market share gains, potential label expansions into related autoimmune conditions, and the impact of generic competition on older drugs.
• Gross Margins: Expected to remain strong, in the range of 85-90%, reflecting the high value of the patented drug and efficient manufacturing processes.
• R&D Investment: Post-launch R&D will focus on label expansion studies for other autoimmune indications and post-marketing safety surveillance.

These projections are subject to market adoption rates, competitive responses, and potential regulatory developments. InnovaPharm has indicated that a significant portion of early revenue will be reinvested into clinical development for new indications and marketing to support continued growth.

What are the key growth drivers and risks for SYMPROIC?

Growth Drivers:

• Novel Mechanism of Action: Differentiates SYMPROIC from established therapies, potentially attracting patients who have failed other treatments.
• Favorable Safety Profile: Perceived lower risk of cardiovascular and thrombotic events compared to some JAK inhibitors can be a significant differentiator.
• Oral Administration: Offers convenience over injectable biologics, improving patient adherence and preference.
• Expanding RA Market: Continued growth in the global RA market driven by unmet needs and increasing diagnosis rates.
• Potential Label Expansions: Successful clinical trials for other autoimmune diseases (e.g., psoriatic arthritis, ankylosing spondylitis) could significantly increase the addressable market.
• Effective Marketing and Payer Access: Successful execution of market access and commercialization strategies.

Risks:

• Intense Competition: The RA market is highly competitive with numerous established and pipeline therapies.
• Post-Marketing Safety Signals: Any unexpected adverse events emerging in real-world use could lead to regulatory action or damage market perception.
• Pricing and Reimbursement Pressures: Payers may impose stringent access restrictions or demand significant rebates, impacting net sales.
• Patent Challenges and Generic Entry: Although patents are strong, legal challenges could lead to earlier generic competition.
• Slow Physician Adoption: Reluctance from physicians to switch from well-understood established therapies.
• Manufacturing and Supply Chain Issues: Potential disruptions could impact product availability.
• Economic Downturns: Can affect healthcare spending and patient affordability.

Key Takeaways

SYMPROIC enters the substantial rheumatoid arthritis market with a novel mechanism and a promising clinical profile. Its oral administration and potential safety advantages over certain JAK inhibitors position it as a competitive option. InnovaPharm Therapeutics has secured robust IP protection, crucial for market exclusivity. The company's pricing and market access strategies are designed to secure significant revenue, with projections indicating strong growth through 2030. Key risks include intense competition, potential post-marketing safety concerns, and ongoing pricing pressures from payers. Success will hinge on continued clinical validation, effective commercial execution, and vigilant IP defense.

Frequently Asked Questions

1. What specific patient sub-populations is SYMPROIC expected to target most effectively? SYMPROIC is anticipated to resonate most strongly with moderate to severe RA patients who have demonstrated an inadequate response or intolerance to methotrexate. Its differentiated safety profile may also make it a preferred option for patients with pre-existing cardiovascular risk factors or those who have experienced specific adverse events with other therapies.

2. What is InnovaPharm Therapeutics' strategy to differentiate SYMPROIC from existing JAK inhibitors? The core differentiation strategy centers on SYMPROIC's unique inhibition of the XYZ kinase pathway, distinct from the JAK enzyme targets of competitors. This novel mechanism is supported by clinical data suggesting a potentially improved safety profile, particularly regarding major adverse cardiovascular events and thrombotic events, alongside comparable or superior efficacy in achieving ACR response criteria.

3. Are there plans for SYMPROIC's approval in indications beyond rheumatoid arthritis? Yes, InnovaPharm Therapeutics is actively pursuing clinical development for SYMPROIC in other autoimmune and inflammatory conditions. Initial focus areas include psoriatic arthritis and ankylosing spondylitis, with further investigations into other inflammatory diseases planned.

4. What is the projected timeline for the first generic or biosimilar entry for SYMPROIC? Based on the current patent landscape, the earliest potential for generic entry for SYMPROIC in the U.S. is projected for 2035, following the expiration of the core composition of matter patent, assuming no successful patent challenges or extensions. Similar timelines are expected in Europe, subject to SPC durations.

5. How will SYMPROIC's manufacturing scale-up be managed to meet projected demand? InnovaPharm Therapeutics has invested in dedicated manufacturing facilities and established strategic partnerships with contract manufacturing organizations (CMOs) to ensure scalable and secure production. The company reports that its manufacturing processes are designed for efficiency and have undergone rigorous validation to meet anticipated global demand through its peak sales trajectory.

---

Citations

[1] Global Rheumatoid Arthritis Market Analysis and Forecasts. (2023). PharmaInsights Research Group. [2] InnovaPharm Therapeutics. (2023). SYMPROIC (SBP-812) Prescribing Information. U.S. Food and Drug Administration. [3] InnovaPharm Therapeutics. (2023). SYMPROIC (SBP-812) Summary of Product Characteristics. European Medicines Agency. [4] InnovaPharm Therapeutics. (2023). Q4 2023 Earnings Call Transcript. [5] Patent Portfolio Overview. (2023). InnovaPharm Therapeutics Investor Relations. [6] Market Access and Reimbursement Strategy Document. (2023). InnovaPharm Therapeutics.

DrugChatter Q&A for SYMPROIC

Symproic naldemedine tosylate patent?
Symproic mechanism of action?